Company Overview and News

10
Airlines Attempt to Offset Rising Costs Via Baggage Fee Hike

2018-09-20 zacks
In a bid to counter the challenges posed by escalating costs, airlines are on a spree to raise fees for checked bags. Delta Air Lines, Inc. (DAL - Free Report) is the latest carrier to have joined the bandwagon, following similar moves by other industry participants, namely JetBlue Airways Corporation (JBLU - Free Report) and United Continental Holdings, Inc. (UAL - Free Report) late in August. Delta has hiked its first checked bag fee to $30 from the previous $25 and the second checked bag fee to $40 from $35 earlier on domestic routes.
UAL WJA ACDVF AAL RYAOF JBLU SAVE RYAAY ALGT DAL WJAFF AC

 
ALGT / Allegiant Travel Company / PAR INVESTMENT PARTNERS LP - SC 13G (Passive Investment)

2018-09-17 sec.gov
SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
ALGT

 
ALGT / Allegiant Travel Company / PAR INVESTMENT PARTNERS LP - SC 13G (Passive Investment)

2018-09-17 sec.gov
SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
ALGT

13
Bulletproof Investing Performance Update, Week 41

2018-09-13 seekingalpha
It has been six months since I presented four hedged portfolios and 10 top names in week 41 of my Marketplace service (March 8). Here's how everything did.
POOL CMA AGEN NFLX NVDA CHE RHT EPAM WWE TWTR ALGT

 
ALGT / Allegiant Travel Company FORM 8-K (Current Report)

2018-09-13 sec.gov
Document UNITED STATES
ALGT

1
Allegiant's (ALGT) August Traffic Increases, Load Factor Down

2018-09-12 zacks
Allegiant Travel Company (ALGT - Free Report) delivered a mixed traffic report for August. Even though traffic increased substantially on account of rising demand for air travel, load factor (percentage of seats filled with passengers) in the month declined as traffic growth was outpaced by capacity expansion. Traffic for the total system, including scheduled service and fixed fee contract — measured in revenue passenger miles (RPMs) — climbed 14.
SKYW CHRW TRN ALGT

 
Airline Stock Roundup: UAL Hikes Baggage Fees, LUV's New Routes & More

2018-09-05 zacks
In the past week, United Continental Holdings, Inc. (UAL - Free Report) joined JetBlue Airways Corporation (JBLU - Free Report) in increasing fees for checked bags. Apart from the update on baggage fees, United Continental was also in news as a result of the decision to expand its transatlantic network next year.
RYAOF JBLU RYAAY UAL ALGT ALK

17
Busiest Labor Day in the Cards for U.S. Airlines Per A4A

2018-08-29 zacks
According to a projection by Airlines for America (‘A4A’), the trade organization for leading U.S. airlines, companies in the airline space are set to make significant gains in the upcoming Labor Day holiday period (Aug 29–Sep 4). The projection indicates 3.5% more passengers flying to various destinations over the period compared to last year.
AAL JBLU URBN ALGT PBB ALK DAL PSEC

2
Why Is Allegiant Travel (ALGT) Up 15.4% Since Last Earnings Report?

2018-08-24 zacks
A month has gone by since the last earnings report for Allegiant Travel (ALGT - Free Report) . Shares have added about 15.4% in that time frame, outperforming the S&P 500.
ALGN FTI.WI FTI ALGT ROK

 
U.S. budget carrier Spirit expects to raise fares on higher oil prices

2018-08-20 reuters
DENVER (Reuters) - Spirit Airlines expects it will raise passenger fares after years of lower ticket prices as the U.S. budget carrier works to improve margins at a time of rising oil prices, Chief Executive Bob Fornaro said on Monday.
SAVE ALGT

6
New Strong Sell Stocks for August 20th

2018-08-20 zacks
Addus HomeCare Corporation (ADUS - Free Report) is a provider of personal care services to elderly, chronically ill and disabled persons. The Zacks Consensus Estimate for its current year earnings has been revised 11.6% downward over the last 60 days.
BCS MGR AMG CNK 83SF 83SK ADUS ALGT YTRA 47MC

6
Allegiant Travel (ALGT) Stock Declines 12% YTD: Here's Why

2018-08-17 zacks
Shares of Allegiant Travel Company (ALGT - Free Report) have declined 12.3% on a year-to-date basis due to multiple headwinds.
ODFL HD AAWW PSTG HEAR ALGT TRTN OXY ODLF

6
The Zacks Analyst Blog Highlights: GOL Linhas Aereas Inteligentes, Delta Air Lines, Hawaiian Holdings, United Continental Holdings and JetBlue Airways

2018-08-09 zacks
Chicago, IL – August 9, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include GOL Linhas Aereas Inteligentes S.A. (GOL - Free Report) , Delta Air Lines, Inc. (DAL - Free Report) , Hawaiian Holdings, Inc. (HA - Free Report) , United Continental Holdings, Inc.
HA JBLU UCTI CXO UAL TRTN MPC ALK GLUU ROSEU HEAR ALGT DAL FG UCTT ROSE

9
Airline Stock Roundup: GOL's Q2 Loss, DAL's July Traffic Report & More

2018-08-08 zacks - 1
In the past week, Latin American carrier — GOL Linhas Aereas Inteligentes S.A. (GOL - Free Report) — reported wider-than-expected loss per share for the second quarter of 2018. Results were hurt by high costs.
ELY ICFI HA JBLU UAL ALGT ALK DAL

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: 01748X102